

# Christoph Thiemerermann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9206146/publications.pdf>

Version: 2024-02-01

206  
papers

12,047  
citations

23500

58  
h-index

31759

101  
g-index

217  
all docs

217  
docs citations

217  
times ranked

11208  
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation of endogenous hydrogen sulfide by cystathionine $\beta$ -lyase limits renal ischemia/reperfusion injury and dysfunction. <i>Laboratory Investigation</i> , 2008, 88, 1038-1048.	1.7	745
2	The effect of iNOS deletion on hepatic gluconeogenesis in hyperdynamic murine septic shock. <i>Intensive Care Medicine</i> , 2007, 33, 1094-1101.	3.9	570
3	Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. <i>European Journal of Pharmacology</i> , 1990, 182, 591-595.	1.7	498
4	Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. <i>British Journal of Pharmacology</i> , 1993, 108, 786-792.	2.7	370
5	Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10925-10930.	3.3	280
6	Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. <i>British Journal of Pharmacology</i> , 1995, 114, 510-516.	2.7	254
7	ANTI-APOPTOTIC AND ANTI-INFLAMMATORY EFFECTS OF HYDROGEN SULFIDE IN A RAT MODEL OF REGIONAL MYOCARDIAL I/R. <i>Shock</i> , 2009, 31, 267-274.	1.0	224
8	Nitrite-Derived Nitric Oxide Protects the Rat Kidney against Ischemia/Reperfusion Injury In Vivo: Role for Xanthine Oxidoreductase. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 570-580.	3.0	215
9	Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. <i>British Journal of Pharmacology</i> , 1995, 114, 1666-1672.	2.7	203
10	The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. <i>British Journal of Pharmacology</i> , 1995, 116, 2845-2851.	2.7	199
11	The Septic Heart. <i>Chest</i> , 2019, 155, 427-437.	0.4	195
12	Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. <i>Frontiers in Immunology</i> , 2020, 11, 594150.	2.2	182
13	Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. <i>British Journal of Pharmacology</i> , 1993, 110, 177-182.	2.7	170
14	GSK-3 $\beta$ inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat*. <i>Critical Care Medicine</i> , 2005, 33, 1903-1912.	0.4	164
15	ERYTHROPOIETIN ATTENUATES THE TISSUE INJURY ASSOCIATED WITH HEMORRHAGIC SHOCK AND MYOCARDIAL ISCHEMIA. <i>Shock</i> , 2004, 22, 63-69.	1.0	144
16	Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: Effects of the PPAR- $\alpha$ agonist WY14643. <i>Free Radical Biology and Medicine</i> , 2006, 41, 579-589.	1.3	143
17	Lipoproteins in inflammation and sepsis. I. Basic science. <i>Intensive Care Medicine</i> , 2007, 33, 13-24.	3.9	143
18	Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): An International Expert Consensus Initiative for Improvement of Animal Modeling in Sepsis. <i>Shock</i> , 2018, 50, 377-380.	1.0	141

#	ARTICLE	IF	CITATIONS
19	Calpain inhibitor I reduces the activation of nuclear factor- $\kappa$ B and organ injury/dysfunction in hemorrhagic shock. <i>FASEB Journal</i> , 2001, 15, 171-186.	0.2	127
20	Abandon the Mouse Research Ship? Not Just Yet!. <i>Shock</i> , 2014, 41, 463-475.	1.0	126
21	Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. <i>British Journal of Pharmacology</i> , 1993, 108, 776-779.	2.7	123
22	Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy. <i>Anesthesiology</i> , 2017, 126, 115-127.	1.3	123
23	Dexamethasone Ameliorates Renal Ischemia-Reperfusion Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2412-2425.	3.0	106
24	Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18685-18690.	3.3	106
25	Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammation. <i>Critical Care Medicine</i> , 2003, 31, S76-S84.	0.4	103
26	Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. <i>Transplant International</i> , 2006, 19, 919-926.	0.8	102
27	Attenuation of endotoxin-induced multiple organ dysfunction by 1- $\alpha$ -amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. <i>British Journal of Pharmacology</i> , 1996, 118, 261-270.	2.7	100
28	Reconstituted High-Density Lipoprotein Attenuates Organ Injury and Adhesion Molecule Expression in a Rodent Model of Endotoxic Shock. <i>Shock</i> , 2003, 20, 551-557.	1.0	100
29	GLYCOGEN SYNTHASE KINASE 3 $\beta$ AS A TARGET FOR THE THERAPY OF SHOCK AND INFLAMMATION. <i>Shock</i> , 2007, 27, 113-123.	1.0	96
30	Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. <i>British Journal of Pharmacology</i> , 2010, 160, 1892-1902.	2.7	94
31	Role of nitric oxide in the circulatory failure and organ injury in a rodent model of Gram-positive shock. <i>British Journal of Pharmacology</i> , 1996, 119, 1411-1421.	2.7	92
32	The involvement of endothelium-derived relaxing factor in the regulation of renal cortical blood flow in the rat. <i>British Journal of Pharmacology</i> , 1991, 102, 967-973.	2.7	91
33	The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 1321-1333.	1.2	88
34	Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3 $\beta$ . <i>British Journal of Pharmacology</i> , 2006, 147, 575-582.	2.7	87
35	Analysis of the signal transduction in the induction of nitric oxide synthase by lipoteichoic acid in macrophages. <i>British Journal of Pharmacology</i> , 1996, 117, 1163-1170.	2.7	85
36	High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. <i>FASEB Journal</i> , 2001, 15, 1941-1952.	0.2	84

#	ARTICLE	IF	CITATIONS
37	Glycogen synthase kinase-3 $\beta$ inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. <i>Clinical Immunology</i> , 2006, 120, 57-67.	1.4	84
38	TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5109-5114.	3.3	83
39	Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock*. <i>Critical Care Medicine</i> , 2006, 34, 307-313.	0.4	82
40	Glycogen Synthase Kinase-3 $\beta$ Inhibition Attenuates Asthma in Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 431-438.	2.5	82
41	Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: Role of glycogen synthase kinase-3 $\beta$ inhibition*. <i>Critical Care Medicine</i> , 2006, 34, 1489-1496.	0.4	78
42	Scavenging Circulating Mitochondrial DNA as a Potential Therapeutic Option for Multiple Organ Dysfunction in Trauma Hemorrhage. <i>Frontiers in Immunology</i> , 2018, 9, 891.	2.2	78
43	Insulin Reduces Cerebral Ischemia/Reperfusion Injury in the Hippocampus of Diabetic Rats. <i>Diabetes</i> , 2009, 58, 235-242.	0.3	77
44	Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition. <i>British Journal of Pharmacology</i> , 1997, 121, 1824-1830.	2.7	75
45	The Cardioprotective Effects of Preconditioning with Endotoxin, but Not Ischemia, Are Abolished by a Peroxisome Proliferator-Activated Receptor- $\beta$ Antagonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 896-901.	1.3	74
46	Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 179-197.	1.0	72
47	Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. <i>British Journal of Pharmacology</i> , 1993, 108, 557-561.	2.7	71
48	Protective Role of Peroxisome Proliferator-activated Receptor- $\beta$ in Septic Shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1506-1515.	2.5	71
49	Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the $\beta$ -common receptor. <i>Kidney International</i> , 2013, 84, 482-490.	2.6	71
50	Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. , 2015, 151, 32-40.		71
51	Inhibition by spermine of the induction of nitric oxide synthase in J774.2 macrophages: requirement of a serum factor. <i>British Journal of Pharmacology</i> , 1994, 112, 355-356.	2.7	70
52	Reduction of Renal Ischemia-Reperfusion Injury in 5-Lipoxygenase Knockout Mice and by the 5-Lipoxygenase Inhibitor Zileuton. <i>Molecular Pharmacology</i> , 2004, 66, 220-227.	1.0	68
53	Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice*. <i>Critical Care Medicine</i> , 2006, 34, 1168-1177.	0.4	66
54	Free radical scavenging inhibits STAT phosphorylation following in vivo ischemia/reperfusion injury. <i>FASEB Journal</i> , 2006, 20, 2115-2117.	0.2	66

#	ARTICLE	IF	CITATIONS
55	Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: An in vivo study. <i>European Journal of Pharmacology</i> , 2009, 606, 205-209.	1.7	66
56	Glycogen Synthase Kinase-3 $\beta$ Inhibition Reduces Secondary Damage in Experimental Spinal Cord Trauma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 79-89.	1.3	65
57	Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 26.	0.9	61
58	Annexin-A1: Therapeutic Potential in Microvascular Disease. <i>Frontiers in Immunology</i> , 2019, 10, 938.	2.2	61
59	TREATMENT WITH THE GLYCOGEN SYNTHASE KINASE-3 $\beta$ INHIBITOR, TDZD-8, AFFECTS TRANSIENT CEREBRAL ISCHEMIA/REPERFUSION INJURY IN THE RAT HIPPOCAMPUS. <i>Shock</i> , 2008, 30, 299-307.	1.0	60
60	Inhibition of I $\beta$ B kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 1031-42.	1.2	60
61	Delayed circulatory failure due to the induction of nitric oxide synthase by lipoteichoic acid from <i>Staphylococcus aureus</i> in anaesthetized rats. <i>British Journal of Pharmacology</i> , 1995, 114, 1317-1323.	2.7	59
62	ALTERATIONS IN INFLAMMATORY CAPACITY AND TLR EXPRESSION ON MONOCYTES AND NEUTROPHILS AFTER CARDIOPULMONARY BYPASS. <i>Shock</i> , 2007, 27, 466-473.	1.0	59
63	The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 33-49.	3.0	59
64	Selective NOD1 Agonists Cause Shock and Organ Injury/Dysfunction In Vivo. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 595-603.	2.5	58
65	Junctional Adhesion Molecule-C Mediates Leukocyte Infiltration in Response to Ischemia Reperfusion Injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1509-1515.	1.1	57
66	Part I: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Study Design and Humane Modeling Endpoints. <i>Shock</i> , 2019, 51, 10-22.	1.0	57
67	The effects of the endothelin ET <sub>A</sub> receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. <i>British Journal of Pharmacology</i> , 1994, 112, 75-80.	2.7	56
68	GLYCOGEN SYNTHASE KINASE-3 $\beta$ INHIBITORS PROTECT AGAINST THE ORGAN INJURY AND DYSFUNCTION CAUSED BY HEMORRHAGE AND RESUSCITATION. <i>Shock</i> , 2006, 25, 485-491.	1.0	56
69	Glycogen synthase kinase-3 $\beta$ inhibition attenuates the development of ischaemia/reperfusion injury of the gut. <i>Intensive Care Medicine</i> , 2007, 33, 880-893.	3.9	56
70	Refinement of Animal Models of Sepsis and Septic Shock. <i>Shock</i> , 2015, 43, 304-316.	1.0	55
71	Glibenclamide-induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat. <i>British Journal of Pharmacology</i> , 1995, 114, 1273-1281.	2.7	54
72	Peroxisome proliferator-activated receptor- $\beta$ antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia*. <i>Critical Care Medicine</i> , 2006, 34, 1131-1138.	0.4	54

#	ARTICLE	IF	CITATIONS
73	Imidazoquinolinone, Imidazopyridine, and Isoquinolindione Derivatives as Novel and Potent Inhibitors of the Poly(ADP-ribose) Polymerase (PARP): A Comparison with Standard PARP Inhibitors. <i>Molecular Pharmacology</i> , 2008, 74, 1587-1598.	1.0	54
74	Î² Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 94-105.	3.0	53
75	The mechanism of the inhibitory effect of polyamines on the induction of nitric oxide synthase: role of aldehyde metabolites. <i>British Journal of Pharmacology</i> , 1994, 113, 757-766.	2.7	52
76	The contribution of tumour necrosis factor-α and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. <i>British Journal of Pharmacology</i> , 1995, 116, 3309-3315.	2.7	52
77	Ischemic Conditioning Protects the Uremic Heart in a Rodent Model of Myocardial Infarction. <i>Circulation</i> , 2012, 125, 1256-1265.	1.6	52
78	Inhibition of Bruton's TK regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation. <i>British Journal of Pharmacology</i> , 2020, 177, 4416-4432.	2.7	51
79	Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. <i>British Journal of Pharmacology</i> , 1996, 118, 198-204.	2.7	50
80	The selective PPAR <sup>α</sup> antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. <i>Kidney International</i> , 2005, 68, 529-536.	2.6	49
81	Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the Î²-common receptor. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 1021-30.	1.2	49
82	Peroxisome proliferator-activated receptor Î²/Î³ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. <i>Free Radical Biology and Medicine</i> , 2011, 50, 345-353.	1.3	48
83	Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 482-495.	2.9	48
84	Effects of nitric oxide synthase inhibition combined with nitric oxide inhalation in a porcine model of endotoxin shock. <i>British Journal of Pharmacology</i> , 1995, 114, 363-368.	2.7	47
85	ACTIVATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Î²/Î³ ATTENUATES MYOCARDIAL ISCHEMIA/REPERFUSION INJURY IN THE RAT. <i>Shock</i> , 2010, 34, 117-124.	1.0	47
86	Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-Î³ agonism correlates with impaired NLRP3 inflammasome activation. <i>Biochemical Pharmacology</i> , 2013, 85, 257-264.	2.0	47
87	Targeting the NLRP3 inflammasome to Reduce Diet-induced Metabolic Abnormalities in Mice. <i>Molecular Medicine</i> , 2015, 21, 1025-1037.	1.9	47
88	Development and validation of a reinforcement learning algorithm to dynamically optimize mechanical ventilation in critical care. <i>Npj Digital Medicine</i> , 2021, 4, 32.	5.7	47
89	Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion. <i>British Journal of Pharmacology</i> , 1989, 97, 401-408.	2.7	46
90	Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of Gram-negative and Gram-positive shock. <i>British Journal of Pharmacology</i> , 2006, 148, 769-777.	2.7	46

#	ARTICLE	IF	CITATIONS
91	Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe Hemorrhage and Resuscitation. <i>Annals of Surgery</i> , 2017, 265, 408-417.	2.1	46
92	LIVER X RECEPTOR IS A KEY REGULATOR OF CYTOKINE RELEASE IN HUMAN MONOCYTES. <i>Shock</i> , 2008, 29, 468-474.	1.0	44
93	Reduction by prostaglandin E <sub>1</sub> or prostaglandin E <sub>0</sub> of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. <i>British Journal of Pharmacology</i> , 1995, 116, 2435-2440.	2.7	43
94	Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis. <i>Scientific Reports</i> , 2016, 6, 27594.	1.6	43
95	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. <i>Frontiers in Immunology</i> , 2019, 10, 571.	2.2	43
96	Endothelin-1 inhibits platelet aggregation <i>in vivo</i> : a study with <sup>111</sup> indium-labelled platelets. <i>British Journal of Pharmacology</i> , 1990, 99, 303-308.	2.7	42
97	The role of cyclooxygenase-2 in the rodent kidney following ischaemia/reperfusion injury <i>in vivo</i> . <i>European Journal of Pharmacology</i> , 2007, 562, 148-154.	1.7	41
98	Effect of selective blockade of endothelin ET <sub>B</sub> receptors on the liver dysfunction and injury caused by endotoxaemia in the rat. <i>British Journal of Pharmacology</i> , 1996, 119, 479-486.	2.7	39
99	LIVER X RECEPTOR AGONIST GW3965 DOSE-DEPENDENTLY REGULATES LPS-MEDIATED LIVER INJURY AND MODULATES POSTTRANSCRIPTIONAL TNF- $\alpha$ PRODUCTION AND P38 MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION IN LIVER MACROPHAGES. <i>Shock</i> , 2009, 32, 548-553.	1.0	39
100	Peroxisome Proliferator-Activated Receptor- $\alpha$ Contributes to the Resolution of Inflammation after Renal Ischemia/Reperfusion Injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 328, 635-643.	1.3	38
101	Evidence for the Role of Peroxisome Proliferator-Activated Receptor- $\beta/\delta$ in the Development of Spinal Cord Injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 333, 465-477.	1.3	38
102	Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 701-9.	1.2	37
103	New targets of urocortin-mediated cardioprotection. <i>Journal of Molecular Endocrinology</i> , 2010, 45, 69-85.	1.1	36
104	Delayed Administration of Pyroglutamate Helix B Surface Peptide (pHBSP), a Novel Nonerythropoietic Analog of Erythropoietin, Attenuates Acute Kidney Injury. <i>Molecular Medicine</i> , 2012, 18, 719-727.	1.9	35
105	Ribonuclease 1 attenuates septic cardiomyopathy and cardiac apoptosis in a murine model of polymicrobial sepsis. <i>JCI Insight</i> , 2020, 5, .	2.3	34
106	GW0742, A HIGH-AFFINITY PPAR- $\gamma$ AGONIST, INHIBITS ACUTE LUNG INJURY IN MICE. <i>Shock</i> , 2010, 33, 426-435.	1.0	33
107	Inhibition of I $\kappa$ B Kinase Attenuates the Organ Injury and Dysfunction Associated with Hemorrhagic Shock. <i>Molecular Medicine</i> , 2015, 21, 563-575.	1.9	33
108	Gender Dimorphism of the Cardiac Dysfunction in Murine Sepsis: Signalling Mechanisms and Age-Dependency. <i>PLoS ONE</i> , 2014, 9, e100631.	1.1	33

#	ARTICLE	IF	CITATIONS
109	Endotoxin Induces a Second Window of Protection in the Rat Heart as Determined by Using p-Nitro-Blue Tetrazolium Staining, Cardiac Troponin T Release, and Histology. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2276-2280.	1.1	32
110	Senescence and the Aging Immune System as Major Drivers of Chronic Kidney Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 564461.	1.8	32
111	Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice. <i>Frontiers in Immunology</i> , 2019, 10, 2129.	2.2	31
112	GLYCOGEN SYNTHASE KINASE 3 $\beta$ INHIBITION REDUCES THE DEVELOPMENT OF NONSEPTIC SHOCK INDUCED BY ZYMOSAN IN MICE. <i>Shock</i> , 2007, 27, 97-107.	1.0	30
113	Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF- $\kappa$ B. <i>Frontiers in Immunology</i> , 2018, 9, 2996.	2.2	30
114	The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. <i>British Journal of Pharmacology</i> , 2020, 177, 4921-4930.	2.7	30
115	Elevated hepatic 11 $\beta$ -hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3817-3822.	3.3	29
116	Sex-specific regulation of chemokine Cxcl5/6 controls neutrophil recruitment and tissue injury in acute inflammatory states. <i>Biology of Sex Differences</i> , 2015, 6, 27.	1.8	29
117	The synthetic antimicrobial peptide 19-2.5 attenuates septic cardiomyopathy and prevents down-regulation of SERCA2 in polymicrobial sepsis. <i>Scientific Reports</i> , 2016, 6, 37277.	1.6	29
118	Novel applications of recombinant erythropoietin. <i>Current Opinion in Pharmacology</i> , 2006, 6, 184-189.	1.7	28
119	Acute Protective Effects of Simvastatin in the Rat Model of Renal Ischemia-Reperfusion Injury: It Is Never Too Late for the Pretreatment. <i>Journal of Pharmacological Sciences</i> , 2008, 107, 465-470.	1.1	28
120	Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. <i>Infection</i> , 2018, 46, 687-691.	2.3	28
121	A Nonerythropoietic Peptide that Mimics the 3D Structure of Erythropoietin Reduces Organ Injury/Dysfunction and Inflammation in Experimental Hemorrhagic Shock. <i>Molecular Medicine</i> , 2011, 17, 883-892.	1.9	27
122	Mediation of endothelin-1-induced inhibition of platelet aggregation via the ET <sub>B</sub> receptor. <i>British Journal of Pharmacology</i> , 1993, 109, 530-534.	2.7	26
123	Inhibition by N-acetyl-5-hydroxytryptamine of nitric oxide synthase expression in cultured cells and in the anaesthetized rat. <i>British Journal of Pharmacology</i> , 1995, 115, 1175-1181.	2.7	26
124	Endothelin-1-induced reduction of myocardial infarct size by activation of ATP-sensitive potassium channels in a rabbit model of myocardial ischaemia and reperfusion. <i>British Journal of Pharmacology</i> , 1995, 116, 2597-2602.	2.7	25
125	Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow. <i>Critical Care</i> , 2013, 17, R57.	2.5	25
126	Modeling Acute Traumatic Hemorrhagic Shock Injury: Challenges and Guidelines for Preclinical Studies. <i>Shock</i> , 2017, 48, 610-623.	1.0	25



#	ARTICLE	IF	CITATIONS
127	The effects of endotheliumâ€dependent vasodilators on cardiac output and their distribution in the anaesthetized rat: a comparison with sodium nitroprusside. <i>British Journal of Pharmacology</i> , 1988, 95, 986-992.	2.7	24
128	Quantification of microcirculatory blood flow: a sensitive and clinically relevant prognostic marker in murine models of sepsis. <i>Journal of Applied Physiology</i> , 2015, 118, 344-354.	1.2	24
129	Inhibition of Î² Kinase at 24 Hours After Acute Kidney Injury Improves Recovery of Renal Function and Attenuates Fibrosis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	23
130	RvE1 Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction and Enhances Bacterial Clearance. <i>Frontiers in Immunology</i> , 2020, 11, 2080.	2.2	23
131	Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. <i>Molecular Metabolism</i> , 2020, 39, 101009.	3.0	23
132	Role for intracellular plateletâ€activating factor in the circulatory failure in a model of Gramâ€positive shock. <i>British Journal of Pharmacology</i> , 1995, 116, 3191-3198.	2.7	22
133	LYSOPHOSPHATIDIC ACID REDUCES THE ORGAN INJURY CAUSED BY ENDOTOXEMIA-A ROLE FOR G-PROTEIN-COUPLED RECEPTORS AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Î³. <i>Shock</i> , 2007, 27, 48-54.	1.0	22
134	Erythropoietin in the intensive care unit: beyond treatment of anemia. <i>Annals of Intensive Care</i> , 2011, 1, 40.	2.2	22
135	Neutrophil elastase plays a nonâ€redundant role in remodeling the venular basement membrane and neutrophil diapedesis postâ€ischemia/reperfusion injury. <i>Journal of Pathology</i> , 2019, 248, 88-102.	2.1	22
136	Sepsis-3 on the Block. <i>Shock</i> , 2017, 47, 658-660.	1.0	21
137	Models of Coronary Artery Occlusion and Reperfusion for the Discovery of Novel Antiischemic and Antiinflammatory Drugs for the Heart. , 2003, 225, 199-208.		20
138	Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat. <i>Critical Care Medicine</i> , 2008, 36, 550-559.	0.4	20
139	Role of PPAR-Î³ in the development of zymosan-induced multiple organ failure: an experiment mice study. <i>Journal of Inflammation</i> , 2010, 7, 12.	1.5	19
140	Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care. <i>Critical Care</i> , 2012, 16, 229.	2.5	19
141	Effects of the PPAR-Î²/Î³ agonist GW0742 during resuscitated porcine septic shock. <i>Intensive Care Medicine Experimental</i> , 2013, 1, 28.	0.9	19
142	Modeling Cardiac Dysfunction Following Traumatic Hemorrhage Injury: Impact on Myocardial Integrity. <i>Frontiers in Immunology</i> , 2019, 10, 2774.	2.2	19
143	X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure. <i>Frontiers in Immunology</i> , 2020, 11, 581758.	2.2	19
144	Sulprostoneâ€induced reduction of myocardial infarct size in the rabbit by activation of ATPâ€sensitive potassium channels. <i>British Journal of Pharmacology</i> , 1996, 118, 1409-1414.	2.7	18

#	ARTICLE	IF	CITATIONS
145	Novel Synthetic, Host-defense Peptide Protects Against Organ Injury/Dysfunction in a Rat Model of Severe Hemorrhagic Shock. <i>Annals of Surgery</i> , 2018, 268, 348-356.	2.1	18
146	A novel model of reno-cardiac syndrome in the C57BL/6 mouse strain. <i>BMC Nephrology</i> , 2018, 19, 346.	0.8	18
147	The Antimalarial Drug Artesunate Attenuates Cardiac Injury in A Rodent Model of Myocardial Infarction. <i>Shock</i> , 2018, 49, 675-681.	1.0	17
148	Batch effect exerts a bigger influence on the rat urinary metabolome and gut microbiota than uraemia: a cautionary tale. <i>Microbiome</i> , 2019, 7, 127.	4.9	17
149	Activation of Cytokine Synthesis by Systemic Infusions of Lipopolysaccharide and Peptidoglycan in a Porcine Model in Vivo and in Vitro. <i>Surgical Infections</i> , 2007, 8, 495-504.	0.7	16
150	Neuronal Nitric Oxide Synthase is Involved in Vascular Hyporeactivity and Multiple Organ Dysfunction Associated with Hemorrhagic Shock. <i>Shock</i> , 2016, 45, 525-533.	1.0	16
151	Chemical and biochemical characterization and in vivo safety evaluation of pharmaceuticals in drinking water. <i>Environmental Toxicology and Chemistry</i> , 2016, 35, 2674-2682.	2.2	16
152	Endogenously generated arachidonate-derived ligands for TRPV1 induce cardiac protection in sepsis. <i>FASEB Journal</i> , 2018, 32, 3816-3831.	0.2	16
153	Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock. <i>Annals of Surgery</i> , 2021, 273, 1012-1021.	2.1	16
154	Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues. <i>FASEB Journal</i> , 2022, 36, e22107.	0.2	16
155	N <sup>G</sup> -hydroxy-L-arginine prevents the haemodynamic effects of nitric oxide synthesis inhibition in the anaesthetized rat. <i>British Journal of Pharmacology</i> , 1992, 107, 476-480.	2.7	15
156	Inhibition of the release of endothelium-derived relaxing factor <i>in vitro</i> and <i>in vivo</i> by dipeptides containing N <sup>G</sup> -nitro-L-arginine. <i>British Journal of Pharmacology</i> , 1991, 104, 31-38.	2.7	13
157	The spice of life: Curcumin reduces the mortality associated with experimental sepsis*. <i>Critical Care Medicine</i> , 2006, 34, 2009-2011.	0.4	13
158	MURAMYL DIPEPTIDE ENHANCES THE RESPONSE TO ENDOTOXIN TO CAUSE MULTIPLE ORGAN INJURY IN THE ANESTHETIZED RAT. <i>Shock</i> , 2008, 29, 388-394.	1.0	13
159	The Î²-d-Endoglucuronidase Heparanase Is a Danger Molecule That Drives Systemic Inflammation and Correlates with Clinical Course after Open and Endovascular Thoracoabdominal Aortic Aneurysm Repair: Lessons Learnt from Mice and Men. <i>Frontiers in Immunology</i> , 2017, 8, 681.	2.2	13
160	Beneficial effects of erythropoietin in preclinical models of shock and organ failure. <i>Critical Care</i> , 2007, 11, 132.	2.5	12
161	RECOMBINANT HUMAN ERYTHROPOIETIN PREVENTS LIPOPOLYSACCHARIDE-INDUCED VASCULAR HYPOREACTIVITY IN THE RAT. <i>Shock</i> , 2009, 31, 529-534.	1.0	12
162	Erythropoietin Preserves the Integrity and Quality of Organs for Transplantation After Cardiac Death. <i>Shock</i> , 2011, 35, 126-133.	1.0	12

#	ARTICLE	IF	CITATIONS
163	Erythropoietin in the critically ill: do we ask the right questions?. <i>Critical Care</i> , 2012, 16, 319.	2.5	12
164	Lipidomics Provides New Insight into Pathogenesis and Therapeutic Targets of the Ischemia-â€”Reperfusion Injury. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2798.	1.8	11
165	Inhibition of Brutonâ€™s Tyrosine Kinase Activity Attenuates Hemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats. <i>Annals of Surgery</i> , 2023, 277, e624-e633.	2.1	9
166	Hydrogen sulfide, neurogenic inflammation, and cardioprotection: A tale of rotten eggs and vanilloid receptors*. <i>Critical Care Medicine</i> , 2010, 38, 728-730.	0.4	8
167	Heparan Sulfate Induces Necroptosis in Murine Cardiomyocytes: A Medical-In silico Approach Combining In vitro Experiments and Machine Learning. <i>Frontiers in Immunology</i> , 2018, 9, 393.	2.2	8
168	A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 701275.	2.2	7
169	â€”Preconditioningâ€” with Low Dose Lipopolysaccharide Aggravates the Organ Injury / Dysfunction Caused by Hemorrhagic Shock in Rats. <i>PLoS ONE</i> , 2015, 10, e0122096.	1.1	7
170	Pharmacological Inhibition of FAK-Pyk2 Pathway Protects Against Organ Damage and Prolongs the Survival of Septic Mice. <i>Frontiers in Immunology</i> , 2022, 13, 837180.	2.2	7
171	Reduction of infarct size in a rat model of regional myocardial ischemia and reperfusion by the synthetic peptide DAHK. <i>Critical Care Medicine</i> , 2006, 34, 1955-1959.	0.4	5
172	Mitochondrial DNA in Acute Kidney Injury: Chicken or Egg?. <i>Shock</i> , 2018, 49, 352-353.	1.0	5
173	Inhibition of Macrophage Migration Inhibitory Factor Activity Attenuates Haemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats. <i>Frontiers in Immunology</i> , 2022, 13, 886421.	2.2	5
174	Targeting CCR2. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 150-151.	2.5	4
175	Catecholamines and the Septic Heart. <i>Shock</i> , 2013, 39, 404-405.	1.0	4
176	Pleiotropic Effects of Atorvastatin in Experimental Sepsis. <i>Shock</i> , 2014, 41, 458-459.	1.0	4
177	Does Insulin Protect the Brain in Mice and Man with Sepsis?. <i>Shock</i> , 2015, 44, 287.	1.0	4
178	Relative Adrenal Insufficiency in Cardiogenic Shock. <i>Shock</i> , 2017, 48, 498-499.	1.0	4
179	Delayed activation of PPAR-Î²/Î³ improves long-term survival in mouse sepsis: effects on organ inflammation and coagulation. <i>Innate Immunity</i> , 2018, 24, 262-273.	1.1	4
180	Editorial: Translational Insights Into Mechanisms and Therapy of Organ Dysfunction in Sepsis and Trauma. <i>Frontiers in Immunology</i> , 2020, 11, 1987.	2.2	4

#	ARTICLE	IF	CITATIONS
181	Humane End Points in Experimental Models of Septic Shock. Shock, 2013, 39, 541-542.	1.0	3
182	Immunohistochemistry of Kidney $\alpha$ -SMA, Collagen 1, and Collagen 3, in A Novel Mouse Model of Reno-cardiac Syndrome. Bio-protocol, 2020, 10, e3751.	0.2	3
183	Mirror, Mirror on the Wall, Is Off-Pump Better Than On-Pump at All?. Shock, 2014, 42, 174-175.	1.0	2
184	Vascular KATP channels protect from cardiac dysfunction and preserve cardiac metabolism during endotoxemia. Journal of Molecular Medicine, 2020, 98, 1149-1160.	1.7	2
185	The Effect of $\beta$ 2-Adrenoceptor Agonists on Leucocyte-Endothelial Adhesion in a Rodent Model of Laparotomy and Endotoxemia. Frontiers in Immunology, 2020, 11, 1001.	2.2	2
186	Advancements in nanomedicines for the detection and treatment of diabetic kidney disease. Biomaterials and Biosystems, 2022, 6, 100047.	1.0	2
187	Niacin as a novel therapy for septic shock?*. Critical Care Medicine, 2011, 39, 410-411.	0.4	1
188	Reduction of the natural Activated protein C pathway activity significantly prevents coagulopathy in a murine model of acute traumatic coagulopathy. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2014, 22, .	1.1	1
189	The Obesity Paradox Revisited. Shock, 2014, 41, 554-555.	1.0	1
190	Caught Between a Rock and a Hard Place. Shock, 2014, 41, 556-557.	1.0	1
191	Selenium and Niacin for Sepsis Therapy. Critical Care Medicine, 2016, 44, 1256-1257.	0.4	1
192	Norepinephrine, the Intensivist's Swiss Army Knife for Circulatory Shock?. Shock, 2016, 46, 106-107.	1.0	1
193	Inhibition of NF- $\kappa$ B Pathway with IKK-16 or Linagliptin Attenuates the Cardiac Dysfunction Associated with Polymicrobial Sepsis in Mice with Preexisting Type 2 Diabetes Mellitus (T2DM). Diabetes, 2018, 67, 483-P.	0.3	1
194	WHAT'S NEW IN SHOCK, MAY 2006. Shock, 2006, 25, 429-431.	1.0	0
195	WHAT'S NEW IN SHOCK, SEPTEMBER 2006?. Shock, 2006, 26, 223-225.	1.0	0
196	WHAT'S NEW IN SHOCK, MAY 2007?. Shock, 2007, 27, 457-460.	1.0	0
197	WHAT'S NEW IN SHOCK, APRIL 2008. Shock, 2008, 29, 427-430.	1.0	0
198	WHAT'S NEW IN SHOCK, SEPTEMBER 2008?. Shock, 2008, 30, 227-230.	1.0	0

#	ARTICLE	IF	CITATIONS
199	WHAT'S NEW IN SHOCK, MARCH 2008. Shock, 2008, 29, 311-314.	1.0	0
200	INCREASED INOTROPISM FOLLOWING PARP INHIBITION IN THE SETTING OF MYOCARDIAL REPERFUSION INJURY. Shock, 2010, 33, 668-669.	1.0	0
201	The effect of uraemia on the duration of arrhythmias in the context of cardioprotective ischaemic conditioning strategies. Heart Asia, 2014, 6, 76-82.	1.1	0
202	Nutritional Support in Critically Ill Patients. Shock, 2014, 41, 87-88.	1.0	0
203	Oxygen in the Heart. Shock, 2017, 47, 531-532.	1.0	0
204	The Response to the Letter to the Editor Titled: "œls Triple Self-plagiarism œOKœ•If Only Made Transparent?"œby Volker R Jacobs, MD, MBA. Shock, 2019, 51, 140-141.	1.0	0
205	Uninephrectomy and class II PI3Kâ€C2Î² inactivation synergistically protect against obesity, insulin resistance and liver steatosis in mice. American Journal of Transplantation, 2021, 21, 2688-2697.	2.6	0
206	ROLE OF CHELATABLE IRON VERSUS MYOGLOBIN IN OXIDATIVE STRESS AFTER CRUSH TRAUMA. Shock, 2010, 33, 552-553.	1.0	0